HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies ABC- type AI alcohol consumption ALK alzheimer's Angiogenesis antibody drug conjugates Apoptosis Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells BCL2A1 BCL6 benign Biofluid biomarker Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation biomarkers Biomarkers Bladder Bladder Cancer Bladder cancer blindness Breast Cancer Breast milk Breast Milk Burkitt lymphoma Cancer Genomics CAR-T-cells Castleman Disease CD10 CD8 CDKN1A Cells Cerebrospinal Fluid Cetuximab Childhood Atopic Dermatitis children Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating tumor cells cognition Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA Cytokine Cytokines Cytotoxic T Cells dementia Dementia Diabetes Differential Expression Differential Gene Expression Analysis diffuse large B-cell lymphoma DLBCL DLBCL COO Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Dysplasia ear EGFR Muatations EMT Endothelial cell epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epstein-Barr Esophageal Cancer Exosomes Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease Feasibility FFPE FGF Ligand Trap Fibrous Tumors FOLFOX7 Gene expression analysis Gene Expression Profiling Gene Signature Analysis Glioblastoma Tumors HCC Head and neck cancer Head and Neck Cancer Heart hepatocellular carcinoma HLA-E HPV HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune Tolerance Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours Immunotherapy immunotherapy Inflammation IRF4 JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Limb ischemia limbal stem cell deficiency LSCD Liquid Biopsy Liver liver disease Lung Lung cancer Lymph Node Metastasis lymphatic Lymphoid Neoplasia Lymphoma Machine Learning machine learning malignant Mechanism of Action Melanoma Mesothelioma metastatic colorectal cancer CRC Microenvironment MicroRNA microRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mTOR pathway multi-omics MUM1 Muscle Mutations NAFLD Nash and Fibrosis Neoantigens Neuroendocrine Tumor Neurologic NKG2A Non-alcoholic fatty liver disease Non-small cell lung cancer nuclease protection assay obesity OBP Oncology Oncology-Biomarker OPSCC Optical imaging Oral cancer Oral Cancer Oral lesion Oral Squamous Cell Carcinoma Oropharyngeal Cancer Osteoclast Ovarian cancer Pan-Cancer Pancreas Pancreatic Cancer Paralysis Pathogenesis pathophysiology Pathway Analysis Pathway analysis PBMCs PCA Cell Lines PD-1 PD-L1 PFAS PFNA PFOS PIP placenta Placenta Plasma Plasma miRNAs PMAIP1 population based Precision medicine predictive biology Predictive Biomarkers Predictive Modeling Progression free-survival Prostate Prostate Cancer qNPA Refractory DLBCL Relapsed DLBCL Reproductive Response rate Reveal Rheumatoid Arthritis Risk Score Sarcoma sarcoma SARS-CoV-2 Sequencing Serum Signaling Inhibitors Signatures single cell Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Synovial Fluid Synovial Sarcoma synthetic miRNA T-Cell T-cells targeted therapeutics Technology Comparison Therapeutic targets Thyroid Cancer tislelizumab TMB tomentosin Toxicity Transcriptome transcriptome profiling Translational Medicine Treatment Outcome Tumor Biology Tumor Heterogeneity Tumor Microenvironment Urothelial carcinoma Uterus vestibular schwannoma VS virus Wound healing Xenograft Tissue

2021

High-dimensional and single-cell transcriptome analysis of tumor microenvironment in angioimmunoblastic T cell lymphoma AITL)

Pritchett, J. C., et al., High-dimensional and single-cell transcriptome analysis of tumor microenvironment in angioimmunoblastic T cell lymphoma AITL), Leukemia 2021. https://doi.org/10.1038/s41375-021-01321-2

View External Link

2020

Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial

Menter, T., et al. Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial.  British Journal of Haematology; 2020 Jun. doi: 10.1111/bjh.16876

Download pdf 858KB

Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up

Zhou H., et al. Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up. Blood Cancer Journal (2020)10:49

Download pdf 1.0MB

2019

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Hicks, S. W., et al. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Hematologica. 2019 Feb 7; 104(8):1633-1639

Download pdf 1.5MB

Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

Ansell, S. M., et al. Nivolumab for Relapsed/Refractory Diffuse Large B-cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology. 2019 Jan 8:37(6):481-489

Download pdf 873KB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

PQR309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy.

Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].

PMID: 29066507

View External Link

2017

Page last updated November 29, 2022